Overview

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Opicapone
Repaglinide